Literature DB >> 14618630

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

Jocelyn Céraline1, Marion D Cruchant, Eva Erdmann, Philippe Erbs, Jean-Emmanuel Kurtz, Brigitte Duclos, Didier Jacqmin, Dominique Chopin, Jean-Pierre Bergerat.   

Abstract

Androgen receptor (AR) mutations that modify both the ligand binding and the transactivation capacities of the AR represent one of the mechanisms involved in the transition of prostate cancer (PCa) from androgen-dependent to androgen-independent growth. We use a yeast-based functional assay to detect and analyze mutant ARs in PCa. We report the detection of 2 different mutant ARs within the same metastatic tumour sample harvested in a patient with advanced PCa who had escaped androgen deprivation. Concomitantly to the widely described T877A mutant AR, we identified an additional double mutant AR harboring the nonsense mutation Q640Stop just downstream the DNA binding domain together with the T877A point mutation. This type of mutation, which leads to a c-terminal truncated AR, has not been described yet in PCa. Using luciferase reporter assays we demonstrated that this truncated AR exhibited constitutive transactivation properties. In conclusion, our data suggest that mutation-induced constitutive activation of the AR could be a mechanism used by PCa cells to escape androgen deprivation. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14618630     DOI: 10.1002/ijc.11404

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  Androgen receptor repression of GnRH gene transcription.

Authors:  Melissa J Brayman; Patricia A Pepa; Sara E Berdy; Pamela L Mellon
Journal:  Mol Endocrinol       Date:  2011-11-10

2.  Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7.

Authors:  Friedemann Zengerling; Anca Azoitei; Alexander Herweg; Florian Jentzmik; Marcus V Cronauer
Journal:  World J Urol       Date:  2015-08-29       Impact factor: 4.226

3.  Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells.

Authors:  Konstantin V Golovine; Peter B Makhov; Ervin Teper; Alexander Kutikov; Daniel Canter; Robert G Uzzo; Vladimir M Kolenko
Journal:  Prostate       Date:  2012-05-16       Impact factor: 4.104

Review 4.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

5.  V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer.

Authors:  Bradleigh Whitton; Haruko Okamoto; Matthew Rose-Zerilli; Graham Packham; Simon J Crabb
Journal:  Mol Cancer Ther       Date:  2021-02-09       Impact factor: 6.261

Review 6.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

7.  AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells.

Authors:  Wolfgang Streicher; Friedemann Zengerling; Martin Laschak; Wolfgang Weidemann; Michael Höpfner; Andres J Schrader; Florian Jentzmik; Mark Schrader; Marcus V Cronauer
Journal:  World J Urol       Date:  2012-02-24       Impact factor: 4.226

8.  Androgen receptor repression of gonadotropin-releasing hormone gene transcription via enhancer 1.

Authors:  Melissa J Brayman; Patricia A Pepa; Pamela L Mellon
Journal:  Mol Cell Endocrinol       Date:  2012-08-02       Impact factor: 4.102

Review 9.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

10.  ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.

Authors:  Honglin Chen; Stephen J Libertini; Yu Wang; Hsing-Jien Kung; Paramita Ghosh; Maria Mudryj
Journal:  J Biol Chem       Date:  2009-11-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.